Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Immunoconjugates

Known as: Icon, Immunoconjugate, Immunoconjugates [Chemical/Ingredient] 
Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or… Expand
National Institutes of Health

Related topics

Related topics

40 relations

Narrower (30)

AGS67EAMG 595ANG4043D2C7-(scdsFv)-PE38KDEL
Expand

Broader (2)

AntibodiesImmunologic Factors
BRENTUXIMABBispecific CD19-directed CD3-directed T Cell Engager [EPC]ImmunotherapyImmunotoxicity
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.
PURPOSE Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody… Expand
Highly Cited
2008
Highly Cited
2008
Contribution of linker stability to the activities of anticancer immunoconjugates.
The linker component of antibody-drug conjugates (ADC) is a key feature in developing optimized therapeutic agents that are… Expand
Review
2005
Review
2005
Arming antibodies: prospects and challenges for immunoconjugates
Immunoconjugates—monoclonal antibodies (mAbs) coupled to highly toxic agents, including radioisotopes and toxic drugs… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2005
Highly Cited
2005
Structural characterization of the maytansinoid–monoclonal antibody immunoconjugate, huN901–DM1, by mass spectrometry
Immunoconjugates are being explored as novel cancer therapies with the promise of target‐specific drug delivery. The… Expand
Highly Cited
2005
Highly Cited
2005
In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
Effective antibody-drug conjugates (ADC) combine high drug-linker stability in circulation and efficient intratumoral release of… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Highly Cited
2004
Highly Cited
2004
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.
Antibody-targeted chemotherapy with gemtuzumab ozogamicin (CMA-676, a CD33-targeted immunoconjugate of N-acetyl-gamma… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 6
Highly Cited
2002
Highly Cited
2002
Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer…
The anticancer drug doxorubicin (DOX) has been linked to chimeric BR96, an internalizing monoclonal antibody that binds to a… Expand
Highly Cited
1999
Highly Cited
1999
Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate.
Leukemic blast cells express the CD33 antigen in most patients with acute myeloid leukemia (AML), but this antigen is not… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Highly Cited
1993
Highly Cited
1993
Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates.
Immunoconjugates (BR96-DOX) were prepared between chimeric monoclonal antibody BR96 and the anticancer drug doxorubicin. The… Expand
Highly Cited
1992
Highly Cited
1992
Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
The potential of immunoconjugates of cytotoxic drugs for the treatment of cancer has not yet been realized owing to the… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE